Abstract
A large number of studies have implicated activation of innate immune mechanisms in the pathogenesis of chronic obstructive pulmonary disease (COPD). Accumulation of inflammatory cells, chemokines and pro-inflammatory cytokines is a hallmark of activation of these mechanisms, but only a few studies have focussed on antimicrobial peptides in COPD. These peptides are a central component of innate immunity, and airway epithelial cells and neutrophils in the lung are the main cellular sources. In addition to their direct antimicrobial action, antimicrobial peptides have been shown to display a variety of activities that may implicate them in the pathogenesis of COPD. This is based on the observation that they not only contribute to defense against respiratory pathogens that have been associated with COPD, but may also contribute to the influx of inflammatory cells, activation of adaptive immunity and epithelial remodeling. The aim of this review is to provide an update on the basic biology of antimicrobial peptides in the lung, with a focus on their putative role in COPD. In addition, the implication of this knowledge for future treatment of COPD is discussed.
Keywords: COPD, antimicrobial peptide, defensin, cathelicidin, innate immunity, host defense, drug development
Current Drug Targets
Title: Antimicrobial Peptides in COPD - Basic Biology and Therapeutic Applications
Volume: 7 Issue: 6
Author(s): Robert Bals and Pieter S. Hiemstra
Affiliation:
Keywords: COPD, antimicrobial peptide, defensin, cathelicidin, innate immunity, host defense, drug development
Abstract: A large number of studies have implicated activation of innate immune mechanisms in the pathogenesis of chronic obstructive pulmonary disease (COPD). Accumulation of inflammatory cells, chemokines and pro-inflammatory cytokines is a hallmark of activation of these mechanisms, but only a few studies have focussed on antimicrobial peptides in COPD. These peptides are a central component of innate immunity, and airway epithelial cells and neutrophils in the lung are the main cellular sources. In addition to their direct antimicrobial action, antimicrobial peptides have been shown to display a variety of activities that may implicate them in the pathogenesis of COPD. This is based on the observation that they not only contribute to defense against respiratory pathogens that have been associated with COPD, but may also contribute to the influx of inflammatory cells, activation of adaptive immunity and epithelial remodeling. The aim of this review is to provide an update on the basic biology of antimicrobial peptides in the lung, with a focus on their putative role in COPD. In addition, the implication of this knowledge for future treatment of COPD is discussed.
Export Options
About this article
Cite this article as:
Bals Robert and Hiemstra S. Pieter, Antimicrobial Peptides in COPD - Basic Biology and Therapeutic Applications, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435227
DOI https://dx.doi.org/10.2174/138945006777435227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Regulation of Angiotensin II Receptor Expression
Current Pharmaceutical Design Triptolide Improves Renal Injury in Diabetic Nephropathy Rats through TGF-β1/Smads Signal Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design Systemic Inflammation Induces Endothelial Dysfunction in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease
Current Drug Metabolism Molecular Targets of Mesalazine in Colorectal Cancer
Current Cancer Therapy Reviews Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators
Current Topics in Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Current Pharmaceutical Design Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer
Recent Patents on Nanotechnology State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Vitamins Mediate Immunological Homeostasis and Diseases at the Surface of the Body
Endocrine, Metabolic & Immune Disorders - Drug Targets